Best practices for cardiovascular disease prevention in rheumatoid arthritis: A systematic review of guideline recommendations and quality indicators

Arthritis Care and Research

Volumn 67, Issue 2, 2015, Pages 169-179

  Barber, Claire E H ^a   Smith, Alexa ^b   Esdaile, John M ^c,d   Barnabe, Cheryl ^a   Martin, Liam O ^a   Faris, Peter ^a   Hazlewood, Glen ^a   Noormohamed, Raheem ^e   Alvarez, Nanette ^a   Mancini, G B John ^c   Lacaille, Diane ^c,d   Keeling, Stephanie ^f   Aviña Zubieta, J Antonio ^c,d   Marshall, Deborah ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMORBIDITY; DISEASE ACTIVITY; EXERCISE; HEALTH CARE QUALITY; HUMAN; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; EVIDENCE BASED MEDICINE; FEMALE; MALE;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE;

EID: 84922017975     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22419     Document Type: Review

References (48)

1. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nation-wide cohort study. Ann Rheum Dis 2011;70:929-34.
2. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
3. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
4. Gabriel SE, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2012;24:171-6.
5. Van den Oever IA, van Sijl AM, Nurmohamed MT. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther Adv Musculoskelet Dis 2013;5:166-81.
6. Avina-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013;52:68-75.
7. Desai SS, Myles JD, Kaplan MJ. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 2012;14:R270.
8. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
9. Gossec L, Salejan F, Nataf H, Nguyen M, Gaud-Listrat V, Hudry C, et al. Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013;65:712-7.
10. Keeling SO, Teo M, Fung D. Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center. Clin Rheumatol 2011;30:1311-7.
11. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under-treatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010;69:683-8.
12. Scott IC, Ibrahim F, Johnson D, Scott DL, Kingsley GH. Current limitations in the management of cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 2012;30:228-32.
13. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. Can Med Assoc J 1997;156:1705-12.
14. Lugtenberg M, Burgers JS, Westert GP. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. Qual Saf Health Care 2009;18:385-92.
15. Kotter T, Blozik E, Scherer M. Methods for the guideline-based development of quality indicators: a systematic review. Implement Sci 2012;7:21.
16. Yazdany J, Trupin L, Schmajuk G, Katz P, Yelin EH. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. BMJ Qual Saf 2014;23:659-66.
17. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J 2010;182:E839-42.
18. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
19. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217-9.
20. Sociedad Espanola de Reumatologia. Guias de practica clinica finalizadas: guia de manejo de la gota. 2011. URL: http://www.ser.es/practicaClinica/Guias-practica-clinica/Guias- finalizadas.php.
21. Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 2009;48:436-9.
22. National Institute for Health and Clinical Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults 2009. URL: http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf.
23. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. URL: http://www.sign.ac.uk/guidelines/fulltext/123/index.html.
24. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
25. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
26. The Royal Australian College of General Practitioners. Clinical guideline for the diagnosis and management of early rheumatoid arthritis. 2009. URL: http://www.racgp.org.au/download/documents/Guidelines/Musculoskeletal/racgp-ra- guideline.pdf.
27. Tornero Molina J, Sanmarti Sala R, Rodriguez Valverde V, Martin Mola E, Marenco de la Fuente JL, Gonzalez Alvaro I, et al. Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin 2010;6:23-36.
28. Van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69:1913-9.
29. American College of Rheumatology. Rheumatoid arthritis physician performance measurement set. 2008. URL: http://www.rheumatology.org/Practice/Clinical/Quality/Rheumatoid-Arthritis-Quality-Indicators/.
30. National Institute for Health and Care Excellence. Indicator: the percentage of patients with rheumatoid arthritis aged 30-84 years who have had a cardiovascular risk assessment using a CVD risk assessment tool adjusted for RA in the preceding 15 months. 2012. URL: http://www.nice.org.uk/standards-and-indicators.
31. Petersson IF, Strombeck B, Andersen L, Cimmino M, Greiff R, Loza E, et al. Development of healthcare quality indicators for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 2014;73:906-8.
32. Academy of Medicine of Malaysia. Clinical practice guidelines (CPGs): 2011, management of dyslipidemia. URL: http://www.acadmed.org.my/index.cfm?&menuid=67.
33. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.
34. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46.
35. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223:1-68.
36. Goldstein LB, Bushnell CC, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-84.
37. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 2012;18 Suppl 1:1-78.
38. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women: 2011 update. A guideline from the American Heart Association. Circulation 2011;123:1243-62.
39. Brook RH. The RAND/UCLA appropriateness method. In: McCormick KA, Moore SR, Siegel RA, editors. Methodology perspectives. Rockville (MD): Public Health Service, US Department of Health and Human Services; 1994. p. 59-70.
40. US Preventive Services Task Force. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: US Preventive Services Task Force Reaffirmation Recommendation Statement. Ann Intern Med 2009;150:551-5.
41. Stelfox HT, Straus SE. Measuring quality of care: considering conceptual approaches to quality indicator development and evaluation. J Clin Epidemiol 2013;66:1328-37.
42. National Quality Forum. Measure evaluation criteria. URL: http://www.qualityforum.org/docs/measure-evaluation-criteria.aspx.
43. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
44. Actemra (tocilizumab) prescribing information. South San Francisco: Genentech; 2013. URL: http://www.gene.com/download/pdf/actemra-prescribing.pdf.
45. Rozman B, Praprotnik S, Logar D, Tomsic M, Hojnik M, Kos-Golja M, et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567-9.
46. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100 Suppl 2:ii1-ii67.
47. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
48. Khanna D, Arnold EL, Pencharz JN, Grossman JM, Traina SB, Lal A, et al. Measuring process of arthritis care: The Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum 2006;35:211-37.